Published in Anal Chem on November 18, 2010
Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. Int J Nanomedicine (2015) 0.81
Monitoring insulin aggregation via capillary electrophoresis. Int J Mol Sci (2011) 0.77
Field amplified sample stacking of amyloid beta (1-42) oligomers using capillary electrophoresis. Biomicrofluidics (2016) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol (2008) 2.70
Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci (2009) 2.63
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol (2010) 2.60
Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater (2009) 2.43
Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci U S A (2002) 2.35
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science (2009) 2.30
Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev (2012) 2.26
Protein kinase D: a family affair. FEBS Lett (2003) 2.09
Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U S A (2002) 2.00
Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem (2005) 1.99
Metal-organic frameworks in biomedicine. Chem Rev (2011) 1.93
The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol (2009) 1.92
Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload. Cardiovasc Res (2012) 1.79
The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J Pathol (2012) 1.76
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol (2008) 1.64
Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway. Mol Cell Proteomics (2009) 1.52
Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol (2003) 1.52
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 1.47
Cholestatic bile acids inhibit gap junction permeability in rat hepatocyte couplets and normal rat cholangiocytes. J Hepatol (2005) 1.43
Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev (2013) 1.43
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. Leuk Res (2013) 1.42
Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. Cell Res (2013) 1.42
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol (2007) 1.41
Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A (2002) 1.39
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol (2005) 1.38
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood (2006) 1.38
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood (2009) 1.36
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain (2008) 1.36
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood (2011) 1.35
Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol (2009) 1.33
Protein kinase D controls actin polymerization and cell motility through phosphorylation of cortactin. J Biol Chem (2010) 1.32
Pontocerebellar hypoplasia type 2: a neuropathological update. Acta Neuropathol (2007) 1.32
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol (2005) 1.26
Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. J Biol Chem (2006) 1.26
Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem (2005) 1.26
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev (2003) 1.25
Squalene: A natural triterpene for use in disease management and therapy. Adv Drug Deliv Rev (2009) 1.25
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol (2011) 1.24
Site-directed conjugation of "clicked" glycopolymers to form glycoprotein mimics: binding to mammalian lectin and induction of immunological function. J Am Chem Soc (2007) 1.24
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23
Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid Redox Signal (2007) 1.23
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res (2004) 1.21
Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine (2007) 1.21
Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol (2004) 1.19
Nanotheranostics for personalized medicine. Adv Drug Deliv Rev (2012) 1.19
Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem (2004) 1.19
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol (2010) 1.16
BioMOFs: metal-organic frameworks for biological and medical applications. Angew Chem Int Ed Engl (2010) 1.16
Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials (2003) 1.15
The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem (2009) 1.15
Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance. Autophagy (2013) 1.15
Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. Biochim Biophys Acta (2008) 1.14
On-chip manipulation of protein-coated magnetic beads via domain-wall conduits. Adv Mater (2010) 1.14
Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther (2002) 1.12
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood (2007) 1.12
Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 1.12
Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry (2010) 1.11
Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One (2009) 1.10
Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm (2004) 1.08
A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release (2007) 1.06
Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials (2010) 1.06
Gene therapy in epilepsy: the focus on NPY. Peptides (2006) 1.04
Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiol Dis (2011) 1.04
Autophagy modulates cell migration and β1 integrin membrane recycling. Cell Cycle (2013) 1.04
Antiepileptic effects of botulinum neurotoxin E. J Neurosci (2005) 1.03
Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation (2012) 1.03
Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem (2005) 1.03
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.03
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood (2002) 1.02
Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease. Neurodegener Dis (2012) 1.01
The antidepressant mechanism of Hypericum perforatum. Life Sci (2004) 1.01
"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev (2004) 1.01
Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des (2005) 1.01
A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci (2009) 1.01
JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol Dis (2009) 1.00
Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med (2013) 1.00
Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis (2007) 1.00
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One (2011) 1.00
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A (2014) 1.00
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine (2011) 0.99
The pre-eclampsia gene STOX1 controls a conserved pathway in placenta and brain upregulated in late-onset Alzheimer's disease. J Alzheimers Dis (2010) 0.99
Use of self assembled magnetic beads for on-chip protein digestion. Lab Chip (2005) 0.99
Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem Biophys Res Commun (2006) 0.99